All In Biotech

Drug Trial Radar · NCT06125522

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Jan 10, 2024

Primary completion

Sep 10, 2026

Study completion Sep 10, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Arvinas Estrogen Receptor, Inc.; Carrick Therapeutics Limited; Rigel Pharmaceuticals,Inc.
First posted
Nov 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. This study is divided into separate sub-studies. For Sub-Study C: All the participants will receive vepdegestrant and a medicine called samuraciclib. Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective. Participant will continue to take vepdegestrant and samuraciclib until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.

Conditions

  • Breast Cancer

Interventions

  • vepdegestrantDrug

    Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

  • SamuraciclibDrug

    Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Dose Limiting ToxicitiesTime frame: 28 days
  2. Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
  3. Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
  4. Phase 2: Percentage of Participants With Objective Response by investigator assessmentTime frame: Up to approximately 1 year
  5. Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
  6. Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.Time frame: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Clinical and Translational Research Unit (CTRU)

    Palo Alto, California

  • Stanford Cancer Institute - Clinical Trials Office

    Palo Alto, California

  • Stanford Women's Cancer Center

    Palo Alto, California

  • UCHealth Poudre Valley Hospital

    Fort Collins, Colorado

  • UCHealth Harmony

    Fort Collins, Colorado

  • UCHealth Greeley Hospital

    Greeley, Colorado

  • UCHealth - Medical Center of the Rockies

    Loveland, Colorado

  • Memorial Hospital East

    Shiloh, Illinois

  • Siteman Cancer Center - Shiloh

    Shiloh, Illinois

  • Siteman Cancer Center - St Peters

    City of Saint Peters, Missouri

  • Siteman Cancer Center - West County

    Creve Coeur, Missouri

  • Siteman Cancer Center - North County

    Florissant, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center - South County

    St Louis, Missouri

  • Institut Jules Bordet

    Anderlecht, Bruxelles-capitale, Région de, Belgium

  • Centre Georges François Leclerc

    Dijon, Côte-d'or, France

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

    Roma, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.